Exagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of “Moderate Buy” by Analysts

by · The Markets Daily

Shares of Exagen Inc. (NASDAQ:XGN – Get Free Report) have earned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $14.1667.

XGN has been the topic of several recent analyst reports. BTIG Research lifted their target price on shares of Exagen from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Canaccord Genuity Group lifted their price target on Exagen from $11.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, October 27th. KeyCorp boosted their price objective on Exagen from $12.00 to $15.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 14th. B. Riley reaffirmed a “buy” rating and set a $18.00 target price (up from $15.00) on shares of Exagen in a research report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Exagen in a research note on Wednesday, October 8th.

Read Our Latest Analysis on Exagen

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of XGN. Bridgeway Capital Management LLC boosted its holdings in Exagen by 10.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock worth $194,000 after buying an additional 2,600 shares during the period. Calamos Advisors LLC lifted its position in shares of Exagen by 3.5% during the third quarter. Calamos Advisors LLC now owns 78,090 shares of the company’s stock worth $858,000 after acquiring an additional 2,677 shares in the last quarter. Huntleigh Advisors Inc. boosted its holdings in shares of Exagen by 5.7% in the second quarter. Huntleigh Advisors Inc. now owns 87,861 shares of the company’s stock worth $613,000 after acquiring an additional 4,753 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Exagen in the first quarter valued at $25,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Exagen by 3.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 229,115 shares of the company’s stock valued at $2,518,000 after purchasing an additional 8,499 shares during the period. 75.25% of the stock is owned by institutional investors.

Exagen Price Performance

Shares of NASDAQ:XGN opened at $4.74 on Wednesday. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 1.35. The stock has a market cap of $107.41 million, a PE ratio of -5.15 and a beta of 1.86. The stock’s fifty day simple moving average is $6.78 and its two-hundred day simple moving average is $8.66. Exagen has a 1-year low of $2.67 and a 1-year high of $12.23.

Exagen (NASDAQ:XGN – Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). Exagen had a negative net margin of 29.94% and a negative return on equity of 113.48%. The firm had revenue of $17.24 million during the quarter, compared to analysts’ expectations of $16.90 million. As a group, analysts forecast that Exagen will post -0.88 EPS for the current fiscal year.

Exagen Company Profile

(Get Free Report)

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.

Read More